The short version of prothymosin alpha fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-03-10. Anything still debated is marked as such rather than presented as settled.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Peptide | 28 amino acid residues |
| Molecular weight | Approximately 3108 Da | Depends on acetylation state |
| N-terminal modification | Acetylated | Affects charge and stability |
| Natural source | Fragment of thymosin beta-4 | Cleaved in vivo |
| Sequence length | 28 residues | Synthetic form matches natural |
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
The ions are transferred from ionization source and hold at a punch-valve and injected to MS periodically. The performance of a hand-held Mini-10 mass spectrometer was upgraded with negative ion mode for detecting explosive compounds and hazardous materials at the picogram level, which is highly applicable for airport luggage checking.
== Types == Packaging design may vary largely depending on the functions that are fashioned into different types of packages and containers, and depending on the food products and their functions, such as:
==== Clipper alcohol douse ==== If more than one animal is being branded the clippers must also be washed with alcohol between shaving each animal. This prevents hair particles from building up in the blades of the clippers, whose residue on the animal's skin can cause uneven or failed branding.
Sources: en.wikipedia.org
In centuries past, various kinds of chorea were at times called by names such as Saint Vitus' dance, with little or no understanding of their cause or type in each case. The first definite mention of HD was in a letter by Charles Oscar Waters (1816–1892), published in the first edition of Robley Dunglison's Practice of Medicine in 1842. Waters described "a form of chorea, vulgarly called magrums", including accurate descriptions of the chorea, its progression, and the strong heredity of the disease. In 1846 Charles Rollin Gorman (1817–1879) observed how higher prevalence seemed to occur in localized regions. Independently of Gorman and Waters, both students of Dunglison at Jefferson Medical College in Philadelphia, Johan Christian Lund (1830–1906) also produced an early description in 1860. He specifically noted that in Setesdalen, a secluded mountain valley in Norway, the high prevalence of dementia was associated with a pattern of jerking movement disorders that ran in families. The first thorough description of the disease was by George Huntington in 1872. Examining the combined medical history of several generations of a family exhibiting similar symptoms, he realized their conditions must be linked; he presented his detailed and accurate definition of the disease as his first paper. Huntington described the exact pattern of inheritance of autosomal dominant disease years before the rediscovery by scientists of Mendelian inheritance.
=== Variable phenomena, invariant principle === According to the Paccaya sutta (SN 12.20 and its parallel in SA 296), dependent origination is the basic principle of conditionality which is at play in all conditioned phenomena. This principle is invariable and stable, while the "dependently arisen processes" (paṭiccasamuppannā dhammā) are variable and impermanent. Peter Harvey argues that there is an "overall Basic Pattern that is Dhamma" within which "specific basic patterns (dhammas) flow into and nurture each other in complex, but set, regular patterns.".
Actors appearing in Marvel Television series, such as Charlie Cox (who portrayed Matt Murdock / Daredevil in Daredevil) and Adrianne Palicki (Bobbi Morse / Mockingbird in Agents of S.H.I.E.L.D.), were contractually obliged to appear in a Marvel Studios film if asked. In December 2021, Feige confirmed that Cox would reprise the role of Daredevil in Marvel Studios MCU productions, with Cox first reprising the role in the film Spider-Man: No Way Home (2021). Additionally, Vincent D'Onofrio first reprised his role as Wilson Fisk / Kingpin from Daredevil in the Disney+ series Hawkeye (2021).
Sources: en.wikipedia.org
==== Vacuum system ==== During the drying process, a vacuum of 50–100 microbar is applied, by the vacuum system, to remove the solvent. A two-stage rotary vacuum pump is used, however, if the chamber is large then multiple pumps are needed. This system compresses non-condensable gases through the condenser.
=== Relations with Sichuan warlords and the central government === Part of Liu Wenhui's success stemmed from his connections with other Sichuan warlords who were also graduates of Baoding, including Deng Xihou and Tian Songyao, who stood in contrast with Liu Xiang and Yang Sen, who went to the Sichuan Army Accelerated Training School. Although Liu Wenhui was younger than his competitors, he was able to rise to power faster. By 1932, Liu controlled 68 out of 147 counties (around 46%) of the province, a position he had built through familial and professional relationships with his nephew Liu Xiang and his colleagues from the "Baoding clique". However, while clique and blood ties are popular with scholars as a means of explaining the different alliances in warlord-era Sichuan, Kim Hee-shin notes that there are undoubtedly more factors that determined the power relations and subsuquent conflicts between different polities. Liu's greatest political fear was that the smaller Sichuan warlords would join a coalition against him, an eventuality that occurred during the Two-Liu War. A sign of the close connection between the Baoding graduates was the fact that from 1925 to 1932, the Sichuanese capital of Chengdu was jointly governed by a triumvirate consisting of Liu Wenhui, Deng Xihou, and Tian Songyao. To assist him in this task, Liu Wenhui appointed a subordinate commander, Xiang Chuanyi to administer Chengdu on his behalf and maintain relations with the other warlords.
production of the drug(s) or device(s) being evaluated staff salaries for the designers and administrators of the trial payments to the contract research organization, the site management organization (if used) and any outside consultants payments to local researchers and their staff for their time and effort in recruiting test subjects and collecting data for the sponsor the cost of study materials and the charges incurred to ship them communication with the local researchers, including on-site monitoring by the CRO before and (in some cases) multiple times during the study one or more investigator training meetings expense incurred by the local researchers, such as pharmacy fees, IRB fees and postage any payments to subjects enrolled in the trial the expense of treating a test subject who develops a medical condition caused by the study drug These expenses are incurred over several years. In the US, sponsors may receive a 50 percent tax credit for clinical trials conducted on drugs being developed for the treatment of orphan diseases. National health agencies, such as the US National Institutes of Health, offer grants to investigators who design clinical trials that attempt to answer research questions of interest to the agency. In these cases, the investigator who writes the grant and administers the study acts as the sponsor, and coordinates data collection from any other sites. These other sites may or may not be paid for participating in the study, depending on the amount of the grant and the amount of effort expected from them.
Sources: en.wikipedia.org
It corresponds to the first 28 amino acids of thymosin beta-4, a larger protein found in many tissues. The fragment is acetylated at its N-terminus and is produced synthetically for research and pharmaceutical use. Synthetic and natural forms share the same sequence.
It is usually described as an immunomodulatory peptide rather than a classical hormone. It does not travel to a single distant organ in the manner of an endocrine hormone. Classification varies across sources, and some texts group it with thymic peptides generally.
The broad outline involves immune cell activation, but the specific molecular steps remain under investigation. Different studies report effects on dendritic cells, T cells, and natural killer cells. No single receptor has been confirmed as the sole mediator.
It is a 28-residue synthetic peptide studied as an immune-modulating agent and approved as a drug in some countries. The sequence matches a naturally occurring fragment isolated from thymus tissue. It is not a hormone in the endocrine sense.